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Dual epigenetic targeting with panobinostat and azacitidine in
acute myeloid leukemia and high-risk myelodysplastic syndrome
P Tan1,6, A Wei1,6, S Mithraprabhu1, N Cummings1, HB Liu2, M Perugini3, K Reed1, S Avery1, S Patil1, P Walker1, P Mollee4, A Grigg5,
R D’Andrea3, A Dear2 and A Spencer1
Therapeutic options are limited for elderly patients with acute myeloid leukemia (AML). A phase Ib/II study was undertaken
to evaluate the maximum-tolerated dose (MTD) and preliminary efﬁcacy of the pan-histone deacetylase inhibitor panobinostat
(LBH589) in combination with azacitidine in patients with AML or high-risk myelodysplastic syndrome (MDS) naı¨ve to intensive
chemotherapy. Thirty-nine patients (AML¼ 29, MDS¼ 10) received azacitidine 75mg/m2 subcutaneously (days 1–5) and oral
panobinostat (starting on day 5, thrice weekly for seven doses) in 28-day cycles until toxicity or disease progression. Dose-limiting
toxicities during the phase Ib stage were observed in 0/4 patients receiving 10mg panobinostat, in 1/7 patients (fatigue) receiving
20mg, in 1/6 patients (fatigue) receiving 30mg and in 4/5 patients (fatigue, syncope, hyponatremia and somnolence)
receiving 40mg. In phase II, an additional 17 patients received panobinostat at a MTD of 30mg. The overall response rate
(ORR¼CRþCRiþ PR) in patients with AML was 31% (9/29) and that in patients with MDS was 50% (5/10). After a median follow-up
of 13 months, the median overall survival was 8 and 16 months in patients with AML and MDS, respectively. Increased histone H3
and H4 acetylation was a useful early biomarker of clinical response. Combining panobinostat with azacitidine was tolerable and
clinically active in high-risk MDS/AML patients, warranting further exploration.
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INTRODUCTION
Therapeutic options for older patients with acute myeloid
leukemia (AML) are limited by the higher risk of treatment-related
mortality associated with intensive chemotherapy and poor
treatment outcomes, particularly in patients with an adverse risk
karyotype and secondary AML. Alternative treatment options for
those considered unﬁt for intensive chemotherapy include low-
dose cytarabine (LDAC) and, more recently, hypomethylating
agents. The median survival after LDAC is only 4 months and
therefore remains sub-optimal.1 Randomized studies in patients
with advanced myelodysplastic syndromes (MDS) and low-blast
count AML (20–29%) suggest the beneﬁt of azacitidine over
conventional care options (best supportive care, LDAC, or
intensive chemotherapy).2,3 Decitabine in elderly patients with
AML produces a response rate of 20% and a nonsigniﬁcant
increase in median overall survival (8.5 months vs 5.3 months) for
decitabine (vs supportive care or LDAC).4 An analysis of patients
with AML treated with azacitidine on French and Italian
compassionate access programs reports similar response rates
ranging between 21 and 32%.5,6
In addition to DNA promoter hypermethlyation, genome-wide
studies have revealed widespread aberrant histone H3
hypoacetylation in leukemic cells compared with normal hema-
topoietic cells.7 Epigenetic changes, unlike genetic changes, are
reversible, thus supporting attempts to target the leukemic
epigenome with a combination of hypomethylating agents and
histone deacetylase inhibitors (HDACi). Prior studies have been
limited by the use of less potent HDACi drugs, substantial
treatment-related toxicity and the inability to identify a clinically
relevant biomarker of response.8–14 Concurrent administration of
cell-cycle inhibitory HDAC inhibitors may interfere with the actions
of hypomethylating agents, and prior research suggested that
sequential administration of HDACi after low-dose administration
of hypomethylating agents was optimal for the re-expression of
silenced genes.15 We therefore investigated the tolerability and
efﬁcacy of panobinostat (LBH589), a potent, orally bioavailable,
pan-histone deacetylase inhibitor administered semi-sequentially
after the hypomethylating agent azacitidine.16 We show in the
current study that this schedule is tolerable and efﬁcacious in
patients with both AML and advanced MDS. Furthermore, unlike
prior studies with less potent HDACi, we show that clinical
response is correlated with increased peripheral blood histone
acetylation, thus providing a simple biomarker that enables the
identiﬁcation of patients most likely to beneﬁt from treatment.
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Eligible patients were previously untreated AML (X20% blasts) or poor-risk
MDS patients (intermediate-2 or high risk as per the International
Prognostic Scoring System (IPSS)), not suitable for intensive therapy as
per the physician’s discretion. Patients were required to have Eastern
Cooperative Oncology Group performance status o3, bilirubin p2x the
upper limit of normal (ULN), AST or ALTp3x ULN, serum creatininep1.5x
ULN, life expectancy of at least 3 months and no uncontrolled infection.
Exclusion criteria included the presence of serious medical or psychiatric
conditions, CNS leukemia, uncontrolled hepatitis B or C infection, HIV
infection or other clinically signiﬁcant medical co-morbidities.
Study design and treatment
This open-label, phase Ib/II study conducted at three centers (Alfred
Hospital, Princess Alexandra Hospital and the Austin Hospital) was
approved by and in accordance with the principles of independent
Human Research and Ethics Committees and registered with the Australian
and New Zealand Clinical Trials Registry (ACTRN12610000924055).
All participating patients were required to give written informed consent.
Azacitidine 75mg/m2 was injected subcutaneously on days 1–5.17,18
Panobinostat dose was escalated in cohorts using a 3 3 schema to
determine the maximum-tolerated dose (MTD). The cohort doses of
panobinostat were 10, 20, 30 and 40mg with no intra-patient dose
escalation. After the establishment of MTD, dose expansion was
undertaken to better estimate the tolerability of this dose and provide a
preliminary assessment of efﬁcacy. Panobinostat was administered orally
three times a week (Mon/Wed/Fri) starting on day 5 for seven doses of
each 28-day cycle. The treatment was administered on an outpatient-basis,
with physician-determined use of prophylactic antibiotics, antifungal
azoles and granulocyte colony-stimulating factor.
Assessments
Clinical response. Bone marrow assessment was performed after cycles 1,
3 and 6. For AML, a complete response (CR) required a bone marrow with
5% or fewer blasts, an absolute neutrophil count of 41 109/L and a
platelet count of 4100 109/L.19 A CRi was deﬁned as a CR except for
incomplete peripheral blood neutrophil and/or platelet count recovery.
Partial response (PR) was deﬁned as bone marrow blast reduction of at
least 50% from baseline to 5–25% and meeting the peripheral blood
criteria for CR. Patients failing to meet these criteria were considered
resistant to therapy. MDS responses were classiﬁed according to
International Working Group (IWG) criteria.20
Toxicity. Adverse events (AEs) were graded according to the National
Cancer Institute common terminology criteria for AEs (version 3.0). Dose-
limiting toxicity (DLT) was deﬁned during cycle 1 of therapy. Non-
hematologic grade 3 or 4 toxicity, or grade 4 febrile neutropenia
attributable to investigational therapy, was considered a DLT. If the
toxicity occurred in two or more patients at a single dose level, then that
dose was deemed intolerable and the next lower dose level was expanded
to increase conﬁdence in toxicity assessment at the MTD. Hematologic DLT
was deﬁned as failure to achieve an absolute neutrophil count40.5 109/
liter and/or a platelet count 420 109/liter by day 42 in patients whose
bone marrow biopsy at the end of cycle 1 (days 25–28) showed persistent
marrow hypoplasia (o10%) and blasts less than 5%. Patients were
continued on therapy until disease progression or unacceptable toxicity.
Quality of life (QoL). The European Organization for Research and
Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30: version
3) was administered at baseline and at the beginning of cycles 3 and 6.
Transformation of raw scores into a scale from 0 to 100 was performed to
generate the standardized score according to the following formula:
standardized score¼ [(actual raw score - lowest possible raw score)/
possible raw score range] x 100. For the functional scales, higher scores
indicate better health for each domain. For symptom scales, higher scores
indicate a more severe problem.
Statistical analysis
The primary objective was to examine the safety and tolerability of
panobinostat in combination with azacitidine in newly diagnosed high-risk
MDS and AML patients who were not suitable for intensive chemotherapy.
Secondary objectives were to provide preliminary data regarding clinical
outcomes and the correlation between clinical responses and exploratory
biomarkers of outcome. Survival curves were calculated by the Kaplan–
Meier method, and the log-rank test was used to compare groups.
A nonparametric two-tailed Mann–Whitney test was performed to
compare correlative studies and QoL outcomes between groups. Statistical
analyses and graphs were performed using GraphPad Prism 5 software
(GraphPad Software Inc).
Correlative laboratory assessments
Histone acetylation. Cryopreserved cells were thawed at 37 1C for 5min
and subsequently washed with 1x phosphate-buffered saline (PBS). Cells
were ﬁxed in 3.8% paraformaldehyde at 37 1C for 15min and permeabi-
lized in phosphate-buffered saline/0.5% bovine serum albumin/0.3% Triton
X-100. Permeabilized cells were stained with rabbit polyclonal acetyl-H3
(Lys9) and -H4 (Lys8) (Cell Signaling, Danvers, MA, USA) and isotype control
(Rabbit IgG – Cell Signaling) for 20min, followed by staining with
respective Alexa Fluor 488 secondary antibodies (Life Technologies,
Mulgrave, Victoria, Australia). Stained cells were acquired on a FACSCalibur
Flow Cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed on
FlowJo V7.6.2 (Treestar, Ashland, OR, USA). The mean ﬂuorescence
intensity from a sample was normalized to the respective screening
sample and expressed as a fold difference.
Nur77 expression. The increase in Nur77 mRNA expression with therapy
relative to baseline expression in patients with peripheral blood blasts was
assessed. RNA was isolated by Trizol from peripheral blood mononuclear
cells. Nur77 mRNA expression was analyzed by real-time PCR. The reaction
volumes of 20 ml contained SYBR Green Buffer and forward and reverse
primers for target genes. The primers used for NUR77 were forward
50-GCTGCAGAATGACTCCACC-30 and reverse 50-ACAGCAGCACTGGGCTTA-30 .
The primer for b-Actin was forward 50-GACAGGATGCAGAAGGAGATTACT-30
and reverse 50-TGATCCACATCTGCTGGAAGGT-30 . Data were normalized to
-Actin and presented as mean fold change compared with the
pretreatment screen sample.
Multiplex mutation screening for recurrent genetic mutations. Bone marrow
samples at baseline were assessed for the presence of mutations in c-KIT,
DNMT3A, FLT3-TKD, IDH1, IDH2, JAK1, JAK2, MPL, NPM1, KRAS and NRAS
by multiplexed mass spectrometry (MassARRAY System, Sequenom, San
Diego, CA, USA). DNA was extracted using a DNeasy Blood & Tissue Kit
according to the manufacturer’s instructions (Qiagen, Hilden, Germany).
Genotyping was carried out using the MassARRAY Compact system
(Sequenom, San Diego, CA, USA). PCR primers were designed using
MySequenom design tools to produce an B100 base pair amplicon
surrounding the variant sites. Oligo sequences are available on request.
PCR reactions using iPLEX consumables, inactivation by shrimp alkaline
phosphatase, extended PCRs, ion exchange puriﬁcation and spotting onto
each SpectroChip II matrix were performed according to the manufac-
turer’s protocols. Extended PCR products were resolved using a matrix-
assisted laser desorption/ionization time-of-light mass spectrometer
(MassARRAY Compact system). Data analysis was performed using the
MassARRAY Typer 4.0 software package (Sequenom, San Diego, CA, USA).
GADD45A CpG1 methylation. The change in growth arrest and DNA
damage-inducible alpha (GADD45A) promoter methylation relative to
baseline in patients with peripheral blood blasts were assessed. Genomic
DNA was extracted from peripheral blood mononuclear cell preparations
using the Qiagen QIAamp DNA Extraction kit according to the
manufacturer’s instructions. Quantitative DNA methylation of the
GADD45A proximal promoter was performed using matrix-assisted laser
desorption/ionization time-of ﬂight mass spectrometry by Sequenom
MassARRAY (Australian Genome Research Facility, St Lucia, Brisbane,
Australia) on bisulphite-converted genomic DNA.
RESULTS
Study population
A total of 39 patients were enrolled between January 2010 and
January 2012. There were 29 patients with AML and 10 patients with
high-risk MDS. Patient characteristics are listed in Table 1. The median
age of patients enrolled was 69 years, with 75% of the study
population aged 65 years or over. The majority of patients with AML
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had myelodysplasia-related changes (60%).21 Adverse-risk karyotype
(according to Grimwade et al) was present in 40% of AML cases.22
Patients with MDS had either intermediate-2 (70%) or high risk (30%),
based on the International Prognostic Scoring System.23 There were
four patients with AML who were under 65 years and were
considered not eligible for intensive induction therapy as they were
diagnosed with an antecedent hematological disorder and in addition
had adverse risk cytogenetics (n¼ 2) or severe comorbidities (n¼ 2).
Dose escalation and treatment
During the phase Ib panobinostat dose escalation stage, DLTs
were recorded in 0/4 patients (10mg), 1/7 patients (20mg), 1/6
patients (30mg) and 4/5 patients (40mg) (Table 2). In the 40mg
cohort, dose-limiting grade 3 non-hematologic toxicities included
fatigue, syncope, hyponatremia and somnolence; thus, 30mg was
declared the MTD for expansion and a further 17 patients were
treated for preliminary efﬁcacy assessment. The median number
of cycles received was six (range 1–30 cycles).
Toxicities
Table 2 shows the incidence of AEs of any grade that occurred in
X10% of patients during the ﬁrst cycle. AEs, regardless of drug
attribution, were reported. The most frequently observed grade
3–4 AEs in the expanded 30mg panobinostat cohort were febrile
neutropenia (22%), nausea (17%), infection (17%), dyspnea (17%)
and fatigue (13%). The most common grade 1–2 toxicities were
fatigue (52%) and injection site reactions (52%) (Table 2). The
frequency of grade 3 or higher toxicities beyond cycle 1 is shown
in Supplementary Table 2. Over the course of treatment, the
majority of patients experienced grade 3 or higher hematological
toxicity related to therapy (anemia (87%), neutropenia (96%) and
thrombocytopenia (92%)) (Supplementary Table 2). The causes for
study therapy discontinuation were disease progression (n¼ 20),
serious infection (n¼ 5), patient choice (n¼ 3), cardiac medica-
tions for atrial ﬁbrillation contraindicating the use of panobinostat
due to risk of QTc prolongation (n¼ 2) and stem cell transplanta-
tion (n¼ 1). There were three patients with cardiac complications
during the study. One patient developed pericardial effusion with
leukemic inﬁltration and two patients developed atrial ﬁbrillation.
Investigational therapy was ceased in the patients with atrial
ﬁbrillation, as both patients commenced sotalol therapy, which
prolonged the QTc interval. Two patients with transformed
myeloﬁbrosis (one associated with MDS and the other with
AML) developed signiﬁcant ascites during therapy and required
intermittent abdominal paracentesis. Death from any cause within
30, 60 and 90 days of commencing trial therapy occurred in one
(3%), six (15%) and 10 (25%) patients, respectively. No deaths were
attributed to study drug.
Clinical responses
Among the 29 patients with AML, three achieved CR/CRi (10%)
and six achieved PR (21%), for an overall response rate (ORR)
(CRþCRiþ PR) of 31% (Table 3). Of the 10 patients with MDS,
four achieved a CR or marrow CR (40%) and one patient had a PR
(10%), for an overall response rate of 50%. Response according to
International Working Group criteria occurred after one cycle in
ﬁve patients, three cycles in eight patients and six cycles in three
patients. At a median follow-up of 13 months, the median overall
survival (OS) was 8 months for patients with AML and 16 months
for patients with MDS (Figure 1a). Although clinical response
rates (CRþ CRiþ PR) were similar for patients with intermediate
risk (28%) and adverse risk (25%) AML karyotype, median OS was
longer for patients with intermediate risk (11 months) compared
with adverse risk (7 months; P¼ 0.04) cytogenetics (Figure 1b).
Patients with AML resistant to azacitidine and panobinostat
continued to receive treatment for 1–17 cycles (mean¼ 6 cycles)
(Supplementary Table 1). This group of patients had stable,
nonprogressive disease. Median OS for patients achieving a
clinical response was 13 months. Surprisingly, median OS was 7
months in patients with resistant disease but evaluable for
response at the end of cycle 1 (Figure 1c). In the 31 patients who
ceased study therapy, subsequent therapies included palliatio-
n±oral chemotherapy (hydroxyurea or thioguanine) (n¼ 27),
LDAC (n¼ 2), reduced-intensity conditioned haploidentical stem
cell transplantation (n¼ 1) or other investigational therapy
(n¼ 1).
Cessation of azacitidine therapy in previously stable MDS
patients for reasons other than progression has been asso-
ciated with rapid loss of response and short survival.24 We
observed similar changes in six patients who ceased study
therapy for reasons other than disease progression, mainly
infection. These patients developed rapidly progressive disease
(mean time¼ 59 days) in the peripheral blood soon after
cessation of investigational therapy, highlighting the potential
importance of these agents in limiting disease progression
without necessarily eliminating bulk disease (Supplementary
Figure 2).
For patients with MDS, median OS was 32 months for
responders (CR, marrow CR and PR) and 11 months for patients
with progressive disease. Median time to AML progression was
not reached in this MDS cohort (Figure 1d).
Table 1. Summary of patient characteristics


















AML with MRC 17 (59)
AML NOS 10 (34)







Abbreviations: AML, acute myeloid leukemia; ECOG PS, Eastern Coopera-
tive Oncology Group Performance Score; IPSS, International Prognostic
Scoring System; MDS, myelodysplastic syndrome; MRC, myelodysplasia-
related changes based on the presence of either (1) previously
documented MDS or MDS/myeloproliferative neoplasm (MPN), (2) specific
myelodysplasia-related cytogenetic abnormalities, or (3) dysplasia in 50%
or more of the cells in 2 or more myeloid lineages; NOS, not otherwise
specified; WBC, white blood cell count; WHO, World Health Organisation.
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Quality of life
Median QoL scores at diagnosis and at the beginning of cycles
three and six according to clinical outcome are shown in
Supplementary Table 3. Clinical response was not associated with
signiﬁcant improvements to global QoL or functional health status
after three or six cycles of therapy. In terms of symptom scales, the
highest median scores at baseline were for fatigue (44; 95%
conﬁdence interval (CI) 36–54), dyspnea (33; 95% CI 20–43) and
appetite loss (33; 95% CI 17–39). By cycle six, symptom scores in
clinical responders and nonresponders were 28 vs 56 (P¼ 0.067)
for fatigue, 0 vs 33 (P¼ 0.214) for dyspnea and 0 vs 33 (P¼ 0.262)
for appetite loss. None of these differences reached statistical
signiﬁcance (Supplementary Table 3).
Correlative studies
Histone H3 and H4 acetylation in peripheral blood mononuclear
cells was assessed quantitatively by ﬂow cytometry as described
previously.25,26 A representative example is shown in
Supplementary Figure 1. Dynamic changes in histone acetylation
from serial blood samples during cycle one from 17 patients are
shown in Figures 2a and b. No increase in acetylation status of
histones H3 and H4 was observed on day 5 after treatment with
azacitidine only for 5 days (Figures 2a and b). Commencement of
panobinostat on day 5, however, led to signiﬁcant increases in H3
(Figure 2a) and H4 (Figure 2b) acetylation, peaking on D12–19
(7–14 days after starting panobinostat) and returning to baseline
levels by D25 (6 days after ceasing panobinostat). The fold-
increase in histone H4 acetylation during cycle one corresponded
to increase in panobinostat dose (Figure 2c). Increased acetylation
also correlated signiﬁcantly with later clinical response, as maximal
clinical beneﬁt for the majority of patients occurred between
cycles three and six of therapy. The clinical response in patients
with a 50% increase in blood mononuclear cell H4 acetylation by
day 19, relative to day 5, was 46%, compared with a response rate
of 0% in patients without demonstrable changes in global histone
acetylation status (Figure 2d).
Examination of methylation changes within leukemic blasts was
assessed in patients with elevated circulating blasts in the
peripheral blood and available serial blood samples. We have
Table 2. Summary of reported toxicities


























n (%) n n n n n (%) n (%) n n
Fatigue 20 (60.0) 4 1 DLT 12 (52) 3 (13)
(1 DLT)
1 3 DLTsa
Injection site reaction 23 (58.0) 4 4 12 (52) 3
Nausea 18 (45.0) 2 2 7 (30) 4 (17) 3
Anorexia 12 (30.0) 1 1 7 (30) 1 (4) 2
Diarrhea 11 (28.0) 1 1 6 (26) 1 (4) 2




Constipation 8 (20.0) 1 6 (26) 1 (4)
Vomiting 8 (20.0) 1 1 5 (22) 1
Dyspnea 7 (18.0) 1 1 (4) 4 (17) 1
Bleeding 9 (22.5) 2 4 (17) 3
Pain 6 (15.0) 1 4 (17) 1 (4)
Febrile neutropenia 6 (15.0) 5 (22) 1
Fever 5 (12.5) 5 (22)
Mucositis 5 (12.5) 2 1 2 (9)
Hyperglycemia 5 (12.5) 1 1 2 (9) 1
Rash 5 (12.5) 1 2 (9) 1 (4) 1
Headache 4 (10.0) 1 3 (13)
Edema 4 (10.0) 4 (17)
Petechial rash 4 (10.0) 1 1 1 (4) 1
Syncope 1 (3) 1 DLT
Abbreviations: AE, adverse event; CTCAE, Common terminology criteria for adverse events version 3; DLT, dose-limiting toxicity. DLT (deemed related to study
drug): aincludes fatigue related to hyponatremia and somnolence, bincludes 2 x fungal lung infection (Aspergillus) Grade 5.
Table 3. Summary of clinical responses
Panobinostat dose Overall
10mg 20mg 30mg 40mg
AML (n¼ 29)
CR/CRi 1 1 1 3 (10%)
PR 1 1 4 6 (21%)
Overall (CR/CRi/PR) 9 (31%)
Resistant 4 8 2 14 (48%)
Not evaluable 4 2 6 (21%)
MDS (n¼ 10)
CR 1 1 2 (20%)
Marrow CR (mCR) 1 1 2 (20%)
PR 1 1 (10%)
Overall (CR/mCR/PR) 5 (50%)
Stable disease 1 1 (10%)
Progressive disease 1 2 3 (30%)
Not evaluable 1 1 (10%)
% Major hematologic improvement
HI-Erythroid 1 1 1 3/9 (30%)
HI-Platelet 1 1/5 (20%)
HI-Neutrophil 2 2/2 (100%)
Abbreviations: AML, acute myeloid leukemia; CR, complete remission;
CRi, complete remission with incomplete blood count recovery; HI,
hematological improvement; MDS, myelodysplastic syndrome; PR, partial
remission.
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previously reported the adverse prognostic impact of CpG1
hypermethylation in the promoter region of the GADD45A gene.27
Baseline GADD45A methylation was high in patient ID19
(Figure 2e) and fell substantially between days 12–19 before
returning to baseline levels by day 25. Although this patient did
not achieve an objective clinical response, he had stable disease
and received nine cycles of therapy (Supplementary Table 1).
In hemoglobinopathies, treatment with azacitidine has been
reported to reactivate fetal hemoglobin (HbF) production in
erythroid progenitors.28 Thus, HbF may act as a surrogate marker
for azacitidine demethylation activity.9 HbF was assessed by high-
performance liquid chromatography at baseline and monthly in
33 patients during the course of the study. Two patients (ID 1 and
28, Supplementary Table 1) had abnormally elevated HbF levels at
baseline (8.4 and 7%). Both patients achieved a clinical response.
A 50% increase in HbF during therapy occurred in seven patients.
Five of these patients had a clinical response. In one patient (ID 5,
Supplementary Table 1), the rise in HbF occurred at the same time
as clinical disease response. In the other four patients, however,
the rise in HbF was only detected 3–6 months after achievement
of clinical MDS or AML response.
HDAC inhibitors have been reported to induce expression of the
orphan receptor gene NUR77 in vitro, a tumor suppressor gene
known to cause rapidly fatal AML when deleted in mice and which
is commonly silenced in human AML blasts.29,30 Changes in Nur77
mRNA expression in peripheral blood mononuclear cells during
cycle 1 were assessed in 29 patients. This showed a progressive
increase in Nur77 expression that peaked by day 25 of cycle 1
(Figure 2f).
Clinical responses were also assessed relative to known
recurrent AML mutations, as shown in Table 4. Clinical responses
were observed in patients with activating KRAS (3/6), JAK2 (2/2)
and IDH2 (1/3) mutations. It was found that 4/10 (40%) evaluable
patients with AML and an adverse risk karyotype had a clinical
response to azacitidine and panobinostat, including a patient with
mixed lineage leukemia and 3/7 patients with complex risk
karyotype (Supplementary Table 1). Of the ﬁve patients with MDS
who achieved CR/mCR/PR, the karyotypes were normal (n¼ 2),
monosomy 7 (n¼ 1), t(3;3) (n¼ 1) and complex (n¼ 1)
(Supplementary Table 1).
DISCUSSION
The treatment options for elderly patients with AML are
notoriously limited. The focus of this study was to examine the
clinical feasibility and potential therapeutic role of dual epigenetic
targeting therapy with the hypomethylating agent azacitidine
given semi-sequentially with the pan-HDACi panobinostat. In a
phase 1 study exploring the role of panobinostat in hematologic
malignancies, responses were observed in 4/83 (5%) patients with
AML and in 1/11 (9%) patients with MDS. All responses were
recorded at the 60mg panobinostat dose level.16 This study, the
ﬁrst to use the HDACi panobinostat in combination with a
hypomethylating agent, resulted in an overall clinical response
rate of 35% (AML 31%, MDS 50%; Table 3). This compares
favorably to other azacitidine/HDACi combinations, which have
reported response rates ranging between 16 and 41%
(Supplementary Table 4).
Treatment with azacitidine/panobinostat was associated
with low treatment-related mortality and could be administered
in the outpatient setting. In this study, worsening fatigue related
to panobinostat was the dominant DLT and a major contributor
to drug-related AEs at the MTD. At the 30mg panobinostat
dose level, 70% of patients reported fatigue, of which 17% was
grade 3–4 in severity (Table 2). Using patient-reported QoL
scales, fatigue was already the highest ranked symptom at
baseline (Supplementary Table 3), consistent with other
studies describing fatigue as one of the dominant QoL issues
at baseline in AML.31,32 Azacitidine and panobinostat showed a
trend to improving global health status and patient-reported
fatigue in clinical responders after six cycles, suggesting
potential for QoL beneﬁts in patients receiving this epigenetic-
modifying regimen.
Improving the selection of patients most likely to beneﬁt from
treatment remains a major hurdle to the clinical success of
epigenetic-modifying agents in AML. To identify a surrogate
pharmacodynamic marker that would be applicable to the









































Median = 8 months












































Figure 1. Kaplan–Meier analysis of (a) overall survival in patients
with AML and MDS, (b) overall survival in patients with AML
stratified by cytogenetic risk, (c) overall survival in patients with AML
without clinical response to therapy and (d) AML progression-free
survival in patients with MDS.
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patients most likely to beneﬁt from the addition of panobinostat, a
quantitative ﬂow cytometric assay was employed. This revealed
dose-dependent increases in both histone H3 and H4 acetylation
after panobinostat and a strong correlation between acetylation
increases 450% from baseline and clinical response (44 vs 0%)
(Figure 2). This is the ﬁrst time that clinical response has been
linked to increased acetylation in AML/MDS, indicating the
potential utility of this noninvasive biomarker for patient selection
in future studies. Previous studies examining changes in H3 and
H4 acetylation by western blot after vorinostat, entinostat, valproic
acid or sodium phenylbutyrate failed to show a correlation
between acetylation and clinical response.10,12,33–35 The lack of
correlation with previous studies may be attributed to the
increased sensitivity of ﬂow cytometry and the greater potency
of panobinostat compared with other HDAC inhibitors.
In contrast, assessing for changes in methylation or acetylation
status within AML blasts was complicated by the frequent absence
or admixture of leukemic cells with nonmalignant cells in
peripheral blood and the difﬁculties in performing serial bone
marrow examinations to capture dynamic changes in the
epigenome. Previous studies have demonstrated that demethylation
is most evident 7–14 days after commencing hypomethylating
agents and that these changes generally resolve prior to the time
that most studies assess bone marrow response, usually after
4 weeks. By restricting analysis to patients with elevated
circulating blasts in the blood, gene demethylation could be















































































































































Figure 2. Peripheral mononuclear cell histone acetylation changes as assessed by mean fluorescent intensity (MFI) change in (a) histone H3
and (b) histone H4 during cycle 1 of therapy, or (c) according to panobinostat dose on day 19 relative to baseline for histone H4. (d) Patients
with 50% or greater increases in histone H4 acetylation on day 19 relative to day 5 had a higher frequency of clinical response than did
patients with lesser degrees of acetylation. **¼ Po0.01. (e) Dynamic changes in GADD45A CpG1 methylation during cycle 1 in patients with
dominant circulating peripheral blood blasts. (f ) Meanþ s.d of Nur77 gene expression levels in peripheral blood mononuclear cells during
cycle 1.
Table 4. Overview of detected mutations in AML blasts and response
outcome
Gene Mutation Responders (CR/PR) (%)
KRAS G12D/V/A, G13D/A 3/6 (50)
NRAS G13D/V/A, Q61H 0/2 (0)
NPM1 W288C 0/4 (0)
IDH2 R140L/G 1/3 (33)
JAK2 V617F 2/2 (100)
MPL-2 W515L/X 0/2 (0)
DNMT3a R882C/H 0/2 (0)
FLT3 ITD 0/1 (0)
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hypomethylation in relation to azacitidine was not impeded by
the schedule of HDACi employed (Figure 2e).
Nur77 is a conserved orphan nuclear receptor that is a tumor
suppressor associated with the development of AML when deleted
in mice. Recent work has shown that Nur77 is downregulated in
human AML blasts and that HDAC inhibitors restore Nur77
expression, leading to apoptosis in leukemic cells. This study
demonstrated increases in Nur77 expression during the ﬁrst cycle of
therapy in peripheral blood mononuclear cells (Figure 2f). Increased
Nur77 expression speciﬁcally in leukemic cells was conﬁrmed in a
selection of AML cases with a dominance of circulating blasts.
Increased expression of Nur77 on day 25 (relative to baseline)
correlated with clinical response (data not shown).
Although recurrent genetic changes are common in AML, a
particular cytogenetic or molecular abnormality will be present
only in a small subset of patients. Despite this, correlations with
response may be highly informative. In our cohort, clinical
responses were observed in 4/9 evaluable patients with a complex
risk karyotype. Responses were also observed in 3/6 patients with
activating KRAS mutations. Both patients in our study with a JAK2
V617F mutation also responded, extending prior observations that
reported 3/4 responses in patients with JAK2-positive myeloﬁ-
brosis treated with panobinostat.16 The ability of panobinostat to
target JAK2 mutant bone marrow disease provides some rationale
for combining this drug with JAK2 inhibitors in future studies.
Azacitidine/panobinostat was associated with a low early-death
rate (3% by day 30 and 15% by day 60) and was administered on
an outpatient basis. The dominant DLT was fatigue related to
panobinostat, and the MTD was determined to be 30mg thrice
weekly, when started on day 5 of azacitidine. Using patient-
reported outcome scales, fatigue was found to be the highest-
ranked symptom at baseline (Supplementary Table 3), consistent
with other studies on AML showing fatigue to be an important
QoL issue. Therapy with hypomethylating agents has been shown
to improve physical functioning and fatigue, compared with best
supportive care, in elderly patients with MDS.36,37 In this study,
treatment with azacitidine and panobinostat showed a trend to
reduced fatigue after six cycles of therapy in clinical responders vs
nonresponders. No signiﬁcant differences were demonstrated in
any of the patient-reported outcomes, functional or symptom-
based categories. Alternatively, this study was inadequately
powered to detect such changes.
In summary, panobinostat given semi-sequentially with azaciti-
dine was a feasible and promising clinical regimen for patients with
high-risk MDS or AML. The advantages of this combination over
chemotherapy include (1) the low rate of early mortality in elderly
unﬁt patients, (2) the promising response rates in patients with a
poor-risk karyotype, including patients with mixed lineage leukemia,
JAK2 and K-RAS mutant AML, (3) the potential for clinical beneﬁt,
even in patients not achieving a clinical response (median OS
7 months; Figure 1c) and (4) the low rate of AML transformation in
patients with MDS (Figure 1d). The demonstration of increased
acetylation using a simple peripheral blood mononuclear cell ﬂow
cytometry assay during the ﬁrst month provides a clinically relevant
biomarker for deﬁning those most likely to beneﬁt from the
addition of panobinostat to azacitidine-based therapy. Compared
with other standard-of-care approaches, randomized studies to
compare the survival, Qol and cost-effectiveness of these compet-
ing treatment approaches are warranted.
CONFLICT OF INTEREST
AS and AW received research funding from Novartis and Celgene.
ACKNOWLEDGEMENTS
We thank the patients, families and research teams for their involvement in the study.
We acknowledge the provision of panobinostat from Novartis and azacitidine from
Celgene as well as funding support for the study. We thank Dirk Ho¨nemann
(Celgene), Ivo Winiger (Novartis) and Othon Gervasio (Novartis) for their advisory
support. We also acknowledge the following funding bodies for their support of this
research: Victorian Cancer Agency, Snowdome Foundation, Alfred Foundation,
Douglas Kefford, the Leukaemia Foundation of Australia and the National Health
and Medical Research Council.
AUTHOR CONTRIBUTIONS
AS and AW conceived and designed the research; PT, AW, KR and AS collected
and assembled the data; all authors contributed to data analysis and
interpretation; AW and PT wrote the paper; all authors approved the
manuscript.
REFERENCES
1 Burnett A, Milligan D, Prentice A, Goldstone A, Mcmullin M, Hills R et al.
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans
retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in
patients not considered ﬁt for intensive treatment. Cancer 2007; 109: 1114–1124.
2 Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC,
Odchimar-Reissig R et al. Randomized Controlled Trial of Azacitidine in Patients
With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group
B. J Clin Oncol 2002; 20: 2429.
3 Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al.
Efﬁcacy of azacitidine compared with that of conventional care regimens in the
treatment of higher-risk myelodysplastic syndromes: a randomised, open-label,
phase III study. Lancet Oncol 2009; 10: 223–232.
4 Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al.
Multicenter, randomized, open-label, phase III trial of decitabine versus patient
choice, with physician advice, of either supportive care or low-dose cytarabine for
the treatment of older patients with newly diagnosed acute myeloid leukemia.
J Clin Oncol 2012; 30: 2670–2677.
5 Thepot S, Itzykson R, Seegers V, Recher C, Quesnel B, Delaunay J et al. Azacytidine
(AZA) as First Line Therapy in AML: Results of the French ATU Program.
ASH Annual Meeting Abstracts 2009; 114: 843.
6 Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al. Azacitidine
for the treatment of patients with acute myeloid leukemia. Cancer 2012; 118:
1014–1022.
7 Agrawal-Singh S, Isken F, Agelopoulos K, Klein H-U, Thoennissen NH, Koehler G et al.
Genome-wide analysis of histone H3 acetylation patterns in AML identiﬁes
PRDX2 as an epigenetically silenced tumor suppressor gene. Blood 2012; 119:
2346–2357.
8 Maslak P, Chanel S, Camacho L, Soignet S, Pandolﬁ P, Guernah I et al. Pilot study
of combination transcriptional modulation therapy with sodium phenylbutyrate
and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic
syndrome. Leukemia 2005; 20: 212–217.
9 Gore S, Baylin S, Sugar E, Carraway H, Miller C, Carducci M et al. Combined DNA
methyltransferase and histone deacetylase inhibition in the treatment of myeloid
neoplasms. Cancer Res 2006; 66: 6361.
10 Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi S-H et al. Early epigenetic
changes and DNA damage do not predict clinical response in an overlapping
schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood 2009; 114: 2764–2773.
11 Raffoux E, Cras A, Recher C, Boe¨lle P-Y, de Labarthe A, Turlure P et al. Phase 2
clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients
with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget
2010; 1: 34.
12 Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical
activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic
acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:
2302–2308.
13 Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K et al.
Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts)
with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous
Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and
Presence of Other Comorbidities. ASH Annual Meeting Abstracts 2011; 118: 608.
14 Odenike O, Godley LA, Madzo J, Karrison T, Green M, Artz AS et al. A phase I and
pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor
belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
ASCO Meeting Abstracts 2011; 29(15_suppl): 6521.
15 Cameron EE, Bachman KE, Myo¨ha¨nen S, Herman JG, Baylin SB. Synergy of
demethylation and histone deacetylase inhibition in the re-expression of genes
silenced in cancer. Nat Genet 1999; 21: 103–107.
Panobinostat and Azacitidine in MDS and AML
P Tan et al
7
& 2014 Macmillan Publishers Limited Blood Cancer Journal
16 DeAngelo D, Spencer A, Bhalla K, Prince H, Fischer T, Kindler T et al. Phase Ia/II,
two-arm, open-label, dose-escalation study of oral panobinostat administered via
two dosing schedules in patients with advanced hematologic malignancies.
Leukemia 2013; 27: 1628–1636.
17 Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL et al.
Hematologic response to three alternative dosing schedules of azacitidine in
patients with myelodysplastic syndromes. J Clin Oncol 2009; 27: 1850–1856.
18 Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl Goldstein K, Cashen AF et al.
A phase II study of 5 day intravenous azacitidine in patients with myelodysplastic
syndromes. Am J Hematol 2009; 84: 560–564.
19 Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al.
Revised Recommendations of the International Working Group for Diagnosis,
Standardization of Response Criteria, Treatment Outcomes, and Reporting
Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:
4642.
20 Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al.
Clinical application and proposal for modiﬁcation of the International Working
Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
21 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al.
The 2008 revision of the World Health Organization (WHO) classiﬁcation of
myeloid neoplasms and acute leukemia: rationale and important changes. Blood
2009; 114: 937–951.
22 Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al.
Reﬁnement of cytogenetic classiﬁcation in acute myeloid leukemia: determi-
nation of prognostic signiﬁcance of rare recurring chromosomal abnormalities
amongst 5876 younger adult patients treated in the United Kingdom Medical
Research Council trials. Blood 2010; 116: 354–365.
23 Greenberg P, Cox C, Le Beau M. International Scoring System for Evaluating
Prognosis in Myelodysplastic Syndromes. Blood 1997; 89: 2079–2088.
24 Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C et al. Rapid loss
of response after withdrawal of treatment with azacitidine: a case series in
patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic
leukemia. Eur J Haematol 2013; 90: 345–348.
25 Rigby L, Muscat A, Ashley D, Algar E. Methods for the analysis of histone H3 and
H4 acetylation in blood. Epigenetics 2012; 7: 875–882.
26 Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC)
inhibitors as single agents induce multiple myeloma cell death principally
through the inhibition of class I HDAC. Br J Haematol 2013; 162: 559–562.
27 Perugini M, Iarossi D, Kok C, Cummings N, Diakiw S, Brown A et al. GADD45A
methylation predicts poor overall survival in acute myeloid leukemia and
is associated with IDH1/2 and DNMT3A mutations. Leukemia 2012; 27:
1588–1592.
28 Humphries R, Dover G, Young NS, Moore JG, Charache S, Ley T et al. 5-Azacytidine
acts directly on both erythroid precursors and progenitors to increase production
of fetal hemoglobin. J Clin Invest 1985; 75: 547.
29 Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J et al.
Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute
myeloid leukemia. Nat Med 2007; 13: 730–735.
30 Zhou L, Ruvolo V, McQueen T, Chen W, Samudio I, Conneely O et al. HDAC
inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-
associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins
in AML. Leukemia 2012; 27: 1358–1368.
31 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al.
The European Organization for Research and Treatment of Cancer QLQ-C30:
a quality-of-life instrument for use in international clinical trials in oncology. J Natl
Cancer Inst 1993; 85: 365–376.
32 Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M et al.
Parameters detected by geriatric and quality of life assessment in 195 older
patients with myelodysplastic syndromes and acute myeloid leukemia are highly
predictive for outcome. Haematologica 2013; 98: 208–216.
33 Garcia-Manero G, Estey EH, Jabbour E, Kadia T, Estrov Z, Cortes J et al. Phase II
Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed
Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not
Eligible for Clinical Trials Because Poor Performance or Presence of Other
comorbidities. ASH Annual Meeting Abstracts 2010; 116: 604.
34 Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide
hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodys-
plastic syndromes. Blood 2008; 111: 1060–1066.
35 Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. Combined DNA
Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid
Neoplasms. Cancer Res 2006; 66: 6361.
36 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al.
The European Organization for Research and Treatment of Cancer QLQ-C30:
a quality-of-life instrument for use in international clinical trials in oncology. J Natl
Cancer Inst 1993; 85: 365–376.
37 Deschler B, Ihorst G, Platzbecker U, Germing U, Ma¨rz E, de Figuerido M et al.
Parameters detected by geriatric and quality of life assessment in 195 older
patients with myelodysplastic syndromes and acute myeloid leukemia are highly
predictive for outcome. Haematologica 2013; 98: 208–216.
This work is licensed under a Creative Commons Attribution 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by/3.0/
Supplementary Information accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)
Panobinostat and Azacitidine in MDS and AML
P Tan et al
8
Blood Cancer Journal & 2014 Macmillan Publishers Limited
